China 'Bay Area' Calling: Merck KgAA Chooses Guangzhou For New Innovation Center
Executive Summary
Thinking all about scale, China opens the world’s longest sea bridge linking the Pearl River Delta area with Hong Kong and Macao, and the newly-formed 'Bay Area' is already attracting drug makers to look further afield than the traditional Beijing and Shanghai locations.
You may also be interested in...
Embracing China 2.0: AZ, Merck KGaA Set Up Funds, J&J Steps Up Digital Push
AstraZeneca has pledged $1bn to a healthcare fund to support local innovation in China, joining big pharma peers J&J and Merck KGaA in fresh moves to embrace this market, where a new wave of digital technology transformation and fast-shifting trends now favor novel new therapies and the rise of local health start-ups
Changes Encourage Celltrion And Nan Fung To Bet On China Biosimilars Opportunity
Despite increasing competition, Celltrion has leapt into China's growing biosimilar market through a joint venture with Nan Fung, and another draw could lie in the biologics contract manufacturing potential in the country’s developing Greater Bay Area.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.